Journal article
Spinal muscular atrophy care in the COVID-19 pandemic era
Muscle & nerve, Vol.62(1), pp.46-49
07/2020
DOI: 10.1002/mus.26903
PMID: 32329921
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has resulted in reorganization of healthcare settings affecting the delivery of clinical care to patients with spinal muscular atrophy (SMA). There is a concern that patients with SMA may be at increased risk of manifesting severe symptoms of COVID-19. Currently approved therapies for SMA improve survival and motor function; however, their delivery requires an increased exposure to the health system and a dedicated healthcare team. In this study, we discuss consensus recommendations pertaining to care of SMA patients during the pandemic. We highlight that SMA treatments should not be perceived as elective. Decisions regarding the delay of treatments should be made with consideration of the potential risks of COVID-19 exposure and the risk of that delay. We emphasize the importance of collaborative treatment decisions between the patient, family, and healthcare provider, considering any geographic- or institution-specific policies and precautions for COVID-19.
Details
- Title: Subtitle
- Spinal muscular atrophy care in the COVID-19 pandemic era
- Creators
- Aravindhan Veerapandiyan - Department of Pediatrics, Division of Neurology, University of Arkansas for Medical Sciences, Arkansas Children's Hospital, Little Rock, Arkansas, USAAnne M Connolly - Department of Pediatrics, Division of Neurology, Nationwide Children's Hospital, The Ohio State University College of Medicine, Columbus, Ohio, USARichard S Finkel - Experimental Neurotherapeutics, St. Jude Children's Research Hospital, Memphis, Tennessee, USAKapil Arya - Department of Pediatrics, Division of Neurology, University of Arkansas for Medical Sciences, Arkansas Children's Hospital, Little Rock, Arkansas, USAKatherine D Mathews - Department of Pediatrics, University of Iowa Carver College of Medicine, Iowa city, Iowa, USAEdward C Smith - Department of Pediatrics, Division of Neurology, Duke University Medical Center, Durham, North Carolina, USADiana Castro - Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USARussell J Butterfield - Department of Pediatrics and Neurology, University of Utah School of Medicine, Salt Lake City, Utah, USAJulie A Parsons - Department of Neurology and Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USALaurent Servais - MDUK Neuromuscular Center, Department of Pediatrics, University of Oxford, United KingdomNancy Kuntz - Department of Pediatrics, Division of Neurology, Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USAVamshi K Rao - Department of Pediatrics, Division of Neurology, Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USAJohn F Brandsema - Division of Neurology, Children's Hospital of Philadelphia, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USAEugenio Mercuri - Pediatric Neurology, Catholic University; Centro Clinico Nemo, Policlinico Gemelli, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, ItalyEmma Ciafaloni - Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA
- Resource Type
- Journal article
- Publication Details
- Muscle & nerve, Vol.62(1), pp.46-49
- Publisher
- United States
- DOI
- 10.1002/mus.26903
- PMID
- 32329921
- ISSN
- 0148-639X
- eISSN
- 1097-4598
- Language
- English
- Date published
- 07/2020
- Academic Unit
- Neurology; Stead Family Department of Pediatrics; Iowa Neuroscience Institute; Neurology (Pediatrics)
- Record Identifier
- 9984070794002771
Metrics
26 Record Views